Coke and Aurora, in separate statements, each said they were interested in cannabidiol-infused beverages but would not comment on any specifics or talks. The new beverages will be pegged to drinkers who suffer with inflammation, pain or cramping.
While neither company confirmed the talks, Coca-Cola said it was "closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world". "The space is quickly evolving".
Earlier this year, beer giant Molson Coors Brewing said it would make cannabis-infused drinks with Hydropothecary, while Corona-beer maker Constellation Brands invested $4bn more into pot firm Canopy Growth.
"It's going to be more of the "recovery drink" category", the source added.
While recent events have seen adult-beverage makers jump into the infused-beverages space, some believe the non-alcoholic infused-beverage markets may hold the key.More news: Josh Gordon Traded to the New England Patriots, Just As You Suspected
More news: Russia, Turkey agree to demilitarised zone around Idlib
More news: As Apple launches new iPhones, here are flagships it may have discontinued
Have you ever had a cannabis-infused drink?
The legal low-concentrate CBD oil is said to be beneficial for treating a number of complaints as well as promoting sleep, boosting appetite and reducing stress, depression and anxiety.
Both Coke and Aurora's shares on the NY stock market increased with the news, despite reports stating there was no guarantee talks between the companies would be successful.
Aurora's shares surged on the news, jumping as much as 23 percent Monday in NY to $8.
Coke says its an ingredient that could gain ground in wellness beverages globally. Coke is looking to team up with the Canadian marijuana farm Aurora Cannabis to develop the beverages. The drinks would not include THC, or tetrahydrocannabinol, the chemical that produces a high. The first-ever medical treatment derived from a marijuana plant will hit the USA market soon, after regulators in June gave an epilepsy treatment by GW Pharmaceuticals Plc the green light.